Actuate Therapeutics, Inc. (ACTU), a clinical-stage biopharmaceutical company focused on developing treatments for difficult-to-treat cancers, announced that new preclinical data for its investigational oral elraglusib tablet will be presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), scheduled for November 18-20 in Barcelona, Spain.
This is a summary. For the full story, refer to the original source. Public of India presents verified citizen-relevant reporting.